University of Chicago
Chicago, Illinois, 60637, United States
NCT Number: NCT05849181
The goal of this study is to see the effect that a cooling pillow pad called Moona has on sleep quality.
Looking for future studies?
Notify Me21 year–50 year
All sexes
Interventional
Not applicable
Chicago, Illinois, 60637, United States
Obesity and diabetes pose a significant burden on healthcare systems worldwide. Evidence from large cross-sectional and longitudinal epidemiologic studies, and well-designed experimental sleep manipulations, demonstrated that insufficient sleep is a risk factor for obesity-induced insulin resistance and type 2 diabetes. Limited available evidence suggests that optimizing sleep duration and quality in individuals who experience deficient sleep could have beneficial effects on weight maintenance, facilitate weight loss and improve glucose metabolism. It is well known that body temperature impacts sleep. A rapid decline in core body temperature increases the likelihood of sleep initiation and may facilitate an entry into the deeper stages of sleep.
Pharmacological treatment is often prescribed for sleep disturbances, primarily insomnia. But sleep extension with benzodiazepines/sedative-hypnotic agents does not appear to have beneficial effects on metabolism, in fact, these drugs may even have an adverse effect on glucose metabolism. Many people use melatonin as a sleep aid, however, the available data do not support a major role of melatonin in body weight regulation and the evidence supporting melatonin administration in improving glucose metabolism has been mixed.
Limited studies suggest that localized cooling could represent a non-pharmacological strategy to favor sleep onset or improve sleep duration and/or quality.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Moona Device pillow pad
Inactive Moona Device pillow pad
Time frame: Baseline to Day 22
A decrease in time to sleep onset from baseline to day 22 measured in time of day by Wrist Actigraphy Monitoring.
Time frame: Baseline to Day 22
Change in wake time from baseline to day 22 measured in time of day by Wrist Actigraphy Monitoring.
Time frame: Baseline to Day 22
Change in wake time from baseline to day 22 measured by polysomnography. The index is generated by polysomnography software.
Time frame: Baseline to Day 22
Change in Sleep duration from baseline to day 22 measured in minutes by Wrist Actigraphy Monitoring.
Time frame: Baseline to Day 22
Sleep duration measured in minutes by polysomnography.
Time frame: Baseline to Day 22
Change in regularity of sleep from baseline to day 22 measured by Wrist Actigraphy Monitoring. The value is from standard deviation of time of middle of the sleep period.
Time frame: Baseline to Day 22
Change in sleep efficiency from baseline to day 22 measure by a percentage of total sleep time/time in bed from Wrist Actigraphy Monitoring.
Time frame: Baseline to Day 22
Sleep efficiency measure by a percentage of total sleep time/time in bed from polysomnography.
Time frame: through study completion, an average of 1 month
The Matsuda Index of whole body insulin sensitivity, the homeostasis model assessment (HOMA) measures beta cell function and insulin resistance. These changes in glucose homeostasis from baseline to 22 days of Moona Device usage are measured by Oral glucose tolerance test (OGTT).
Time frame: Baseline to Day 22
Detection of within-patient changes in sleep effects reported in a novel Patient-Reported Outcome instrument between baseline and Day 22.
Time frame: Baseline to Day 22
Detection of within-patient change in the perception of sleep quality reported in a novel Patient-Reported Outcome instrument between baseline and Day 22.
Time frame: through study completion, an average of 1 month
Urine samples will be collected at two timepoints before bedtime and in the morning. The secretion of melatonin at these timepoints will result in a numerical value.
Time frame: Baseline to Day 22
Changes in first phase insulin response (ARIg=mu.i^-1.min) from baseline to Day 22 measured by oral glucose tolerance test (OGTT).
Time frame: Baseline to Day 22
Changes in oral disposition index (DIo) from baseline to Day 22 measured in (SI x ARIg = [(mu/l)^-1.min^-1] * [mu.l^-1.min]) by oral glucose tolerance test (OGTT).
Time frame: Baseline to Day 22
Changes in insulinogenic index (change in plasma insulin/change in plasma glucose from 0-30 minutes = (pmol/L)/(mg/dL)) from baseline to Day 22 measured by oral glucose tolerance test (OGTT).
Time frame: Baseline to Day 22
Changes in Mean Absolute Glucose (MAG - mg/dl) from baseline to Day 22 measured by Continuous Glucose Monitoring System (CGMS).
Time frame: Baseline to Day 22
Changes in Coefficient of Variation (CV - mg/dl) from baseline to Day 22 measured by Continuous Glucose Monitoring System (CGMS).
Time frame: Baseline to Day 22
Changes in Standard Deviation (SD-mg/dl) from baseline to Day 22 measured by Continuous Glucose Monitoring System (CGMS).
Time frame: Baseline to Day 22
Changes in Area Under the Curve (AUC - mg/dl) from baseline to Day 22 measured by Continuous Glucose Monitoring System (CGMS).
Time frame: Baseline to Day 22
Changes in Time Spent in Range (TIR - minutes) from baseline to Day 22 measured by Continuous Glucose Monitoring System (CGMS).
Time frame: Baseline to Day 22
Changes in Continuous Overall Net Glycemic Action (CONGA - (mg/dl) per minutes) from baseline to Day 22 measured by Continuous Glucose Monitoring System (CGMS).
Time frame: through study completion, an average of 1 month
The rate of FFA decline will be estimated as a measure of insulin sensitivity at the level of the adipocyte.
Time frame: through study completion, an average of 1 month
GIP levels, secreted by the K cells in the small intestine is an incretin hormone that is released in response to food ingestion and stimulates insulin release. The OGTT will provide these GIP levels.
Time frame: through study completion, an average of 1 month
The change in weight values will be measured by blind scales and anthropometrics measurements.
University of Chicago
Other
Randomized Double-Blind Pilot Study to Examine the Effects of a Localized Body Cooling Technology on Sleep and Metabolism in African, American With Overweight and Obesity
Acronym: Moona
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05616013
Body Weight, Nutrition Disorders
Anniston, Alabama, United States
View Trial DetailsNCT06128265
Body Weight, Nutrition Disorders
Chicago, Illinois, United States
View Trial DetailsNCT07079046
Appetite Regulation, Behavior
Valencia, Spain
View Trial DetailsNCT06712836
Body Weight, Nutrition Disorders
Anaheim, California, United States
View Trial Details